# OnCo record ipatunity130 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ipatunity130/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ipatunity130", "NCT03337724" ;
  schema:name "IPATunity130"@en ;
  schema:description "IPATunity130 tried to confirm a promising early signal for the AKT-blocking tablet ipatasertib with paclitaxel in triple-negative breast cancers carrying PI3K-pathway mutations. It failed: progression and survival were the same with or without the drug, and the ipatasertib programme in breast cancer ended."@en ;
  schema:url <https://onco.cc/trials/ipatunity130/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03337724>, <https://doi.org/10.1158/1078-0432.CCR-24-0465> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/akt/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/pten/> ;
  onco:drugs <https://onco.cc/drugs/ipatasertib/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:trials <https://onco.cc/trials/nct03997123/>, <https://onco.cc/trials/barbican/> .